An Open Label Study of Exploratory Pharmacogenomics and Pharmacologic Effects of Neoadjuvant Oral Temsirolimus in Newly Diagnosed Prostate Cancer Patients Undergoing Radical Prostatectomy Who Have a High Risk of Relapse
Latest Information Update: 03 Nov 2021
Price :
$35 *
At a glance
- Drugs Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Pharmacogenomic; Therapeutic Use
- 21 Nov 2009 New source identified and integrated (M.D. Anderson Cancer Center; 2003-0492).
- 17 Sep 2007 Status changed from in progress to completed.
- 04 Oct 2005 New trial record.